Oral contraceptive therapy reduces serum relaxin‐2 in elite female athletes

In: Journal of Obstetrics and Gynaecology Research · 2016 · vol. 43(3) , pp. 530–535 · doi:10.1111/jog.13226 · PMID:28026087 · W2562227660
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-09

Oral contraceptive therapy significantly reduced serum relaxin-2 levels in elite female athletes, particularly in those with high levels during the luteal phase.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

AIM: Recent investigations have demonstrated that athletes with high relaxin-2 levels have a high risk of anterior cruciate ligament injuries, while athletes taking oral contraceptives (OC) have low relaxin-2 levels. It has not yet been clarified whether taking OC reduces relaxin-2 levels. The purpose of this study was to investigate changes in relaxin-2 levels in athletes taking OC. METHODS: Levels of relaxin-2, estradiol, progesterone, luteinizing hormone and follicle-stimulating hormone were measured in serum samples (n = 183) from 106 elite female athletes. Five athletes with serum relaxin-2 concentrations > 6 pg/mL during the luteal phase were recruited to assess the effect of OC therapy. RESULTS: Serum relaxin-2 concentrations were significantly higher during the luteal phase (n = 57) than in the follicular phase (n = 72), or in athletes on OC therapy (n = 10) (P < 0.001, P < 0.001 and P 6 pg/mL. In 23 athletes, serum relaxin-2 concentrations were measured during both the follicular and luteal phases, revealing that relaxin-2 levels were significantly higher in the luteal phase compared with the follicular phase. In 5 out of 23 athletes, serum relaxin-2 concentrations were > 6 pg/mL in the luteal phase and during the second cycle of OC therapy, relaxin-2 concentrations decreased dramatically to below the detection limit (0.26 pg/mL). CONCLUSIONS: High serum relaxin-2 concentrations were only detected during the luteal phase. In athletes with high relaxin-2 concentrations during the luteal phase, OC therapy decreased serum relaxin-2 levels.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (28)

Source provenance

openalex
last seen: 2026-05-10T11:26:23.695233+00:00
unpaywall
last seen: 2026-06-04T02:00:05.705006+00:00
License: CC0 · commercial use OK